Mineralys Therapeutics, Inc. (MLYS) Stock Forecast & Price Target

Compare

586 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MLYS Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Mineralys

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MLYS Stock 12 Month Forecast

Average Price Target

$43.14

▲(12.02% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Mineralys Therapeutics, Inc. in the last 3 months. The average price target is $43.14 with a high forecast of $52.00 and a low forecast of $26.00. The average price target represents a 12.02% change from the last price of $38.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","53":"$53","19.25":"$19.25","30.5":"$30.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,19.25,30.5,41.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.86,30.64,32.42,34.2,35.98,37.76,39.54,41.32,43.1,44.879999999999995,46.66,48.44,50.22,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.86,29.95846153846154,31.056923076923077,32.15538461538461,33.253846153846155,34.35230769230769,35.45076923076923,36.54923076923077,37.64769230769231,38.746153846153845,39.84461538461539,40.94307692307692,42.041538461538465,{"y":43.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.86,28.64,28.419999999999998,28.2,27.98,27.759999999999998,27.54,27.32,27.1,26.88,26.66,26.44,26.22,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.41,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$43.14

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Caufield

H.C. Wainwright

$42

Buy

9.06%

Upside

Reiterated

09/17/25

Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from H.C. Wainwright

Mohit Bansal

Wells Fargo

$26→$50

Buy

29.84%

Upside

Reiterated

09/11/25

Mineralys Therapeutics price target raised to $50 from $26 at Wells FargoMineralys Therapeutics price target raised to $50 from $26 at Wells Fargo

Richard Law CFA

Goldman Sachs

$32→$52

Buy

35.03%

Upside

Reiterated

09/09/25

Goldman Sachs Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)

Rami Katkhuda

LifeSci Capital

$44

Buy

14.26%

Upside

Reiterated

09/06/25

Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position

Tim Anderson

Bank of America Securities

$43

Buy

11.66%

Upside

Reiterated

09/04/25

Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones

Dennis Ding

Jefferies

$15→$26

Hold

-32.49%

Downside

Reiterated

09/03/25

Jefferies Reaffirms Their Hold Rating on Mineralys Therapeutics, Inc. (MLYS)Jefferies analyst Dennis Ding raised the price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) to $26.00 (from $15.00) while maintaining a Hold rating.

Annabel Samimy

Stifel Nicolaus

$45

Buy

16.85%

Upside

Reiterated

08/13/25

Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)We reiterate our Buy rating on MLYS with a target price of $45.

Seamus Fernandez

Guggenheim

$52→$48

Buy

24.64%

Upside

Reiterated

05/13/25

Mineralys Therapeutics price target lowered to $48 from $52 at GuggenheimMineralys Therapeutics price target lowered to $48 from $52 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Caufield

H.C. Wainwright

$42

Buy

9.06%

Upside

Reiterated

09/17/25

Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from H.C. Wainwright

Mohit Bansal

Wells Fargo

$26→$50

Buy

29.84%

Upside

Reiterated

09/11/25

Mineralys Therapeutics price target raised to $50 from $26 at Wells FargoMineralys Therapeutics price target raised to $50 from $26 at Wells Fargo

Richard Law CFA

Goldman Sachs

$32→$52

Buy

35.03%

Upside

Reiterated

09/09/25

Goldman Sachs Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)

Rami Katkhuda

LifeSci Capital

$44

Buy

14.26%

Upside

Reiterated

09/06/25

Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position

Tim Anderson

Bank of America Securities

$43

Buy

11.66%

Upside

Reiterated

09/04/25

Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones

Dennis Ding

Jefferies

$15→$26

Hold

-32.49%

Downside

Reiterated

09/03/25

Annabel Samimy

Stifel Nicolaus

$45

Buy

16.85%

Upside

Reiterated

08/13/25

Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)We reiterate our Buy rating on MLYS with a target price of $45.

Seamus Fernandez

Guggenheim

$52→$48

Buy

24.64%

Upside

Reiterated

05/13/25

Mineralys Therapeutics price target lowered to $48 from $52 at GuggenheimMineralys Therapeutics price target lowered to $48 from $52 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mineralys Therapeutics, Inc.

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+18.58%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +18.58% per trade.

3 Months

xxx

Success Rate

8/11 ratings generated profit

Average Return

+37.17%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +37.17% per trade.

1 Year

Matthew CaufieldH.C. Wainwright

Success Rate

11/11 ratings generated profit

Average Return

+147.58%

reiterated a buy rating 11 days ago

Copying Matthew Caufield's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +147.58% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+194.29%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +194.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MLYS Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MLYS has received 12 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MLYS average Analyst price target in the past 3 months is 43.14.

Each month's total comprises the sum of three months' worth of ratings.

MLYS Financial Forecast

MLYS Earnings Forecast

Next quarter’s earnings estimate for MLYS is -$0.64 with a range of -$0.74 to -$0.51. The previous quarter’s EPS was -$0.66. MLYS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year MLYS has Outperformed its overall industry.

No data currently available

MLYS Sales Forecast

Next quarter’s sales forecast for MLYS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLYS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MLYS has Preformed in-line its overall industry.

MLYS Stock Forecast FAQ

What is MLYS’s average 12-month price target, according to analysts?

Based on analyst ratings, Mineralys Therapeutics, Inc.’s 12-month average price target is 43.14.

What is MLYS’s upside potential, based on the analysts’ average price target?

Mineralys Therapeutics, Inc. has 12.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MLYS a Buy, Sell or Hold?

Mineralys Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Mineralys Therapeutics, Inc.’s price target?

The average price target for Mineralys Therapeutics, Inc. is 43.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $26.00. The average price target represents 12.02% Increase from the current price of $38.51.

What do analysts say about Mineralys Therapeutics, Inc.?

Mineralys Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of MLYS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mineralys Therapeutics, Inc. (MLYS) Stock Forecast & Price Target

MLYS Analyst Ratings

MLYS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mineralys Therapeutics, Inc.

MLYS Analyst Recommendation Trends

MLYS Financial Forecast

MLYS Earnings Forecast

MLYS Sales Forecast

MLYS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts